Jennifer J. Gao

Jennifer J. Gao

Auto-generated profile, based on publicly available information

Jennifer J. Gao

Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
JGJennifer J Gao
Jennifer J Gao
JCJoyce Cheng
Joyce Cheng
EBErik Bloomquist
Erik Bloomquist
JSJacquelyn Sanchez
Jacquelyn Sanchez
SWSuparna B Wedam
Suparna B Wedam
TPTatiana M Prowell
Tatiana M Prowell

15 May 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PNPreeti Narayan
Preeti Narayan
SWSakar Wahby
Sakar Wahby
JGJennifer J. Gao
Jennifer J. Gao
LALaleh Amiri-Kordestani
Laleh Amiri-Kordestani
AIAmna Ibrahim
Amna Ibrahim
JBJulia A. Beaver
Julia A. Beaver
On March 8, 2019, the FDA granted accelerated approval to atezolizumab in combination with paclitaxel protein-bound for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 [PD-L1 stained tumor-infiltrating immune cells (IC) of any intensity covering ≥1% of the tumor area], as determined by an FDA-approved test. Approval was based on data from IMpassion130, which randomized patients to receive atezolizumab or placebo in combination with paclitaxel protein-bound. Investigator-assessed progression-free survival (PFS) in the intent-to-treat (ITT) and PD-L1–positive populations were coprimary endpoints. After 13-month median follow-up, the estimated median PFS in the PD-L1–positive population was 7.4 months in the atezolizumab arm and 4.8 months in the placebo arm [HR = 0.60; 95% confidence interval (CI), 0.48–0.77]. Overall survival (OS) results were immature with 43% deaths in the ITT population, representing 59% of the OS events required to perform the final OS analysis. Adverse reactions occurring in ≥20% of patients receiving atezolizumab with paclitaxel protein-bound were alopecia, peripheral neuropathies, fatigue, nausea, diarrhea, anemia, constipation, cough, headache, neutropenia, vomiting, and decreased appetite. Accelerated approval was appropriate taking into account the unmet medical need along with the immaturity of the OS results and potential for PFS in the PD-L1–expressing population to predict clinical benefit.

9 November 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PNPreeti Narayan
Preeti Narayan
TPTatiana M. Prowell
Tatiana M. Prowell
JGJennifer J. Gao
Jennifer J. Gao
LFLaura L. Fernandes
Laura L. Fernandes
ELEmily Li
Emily Li
JBJulia A. Beaver
Julia A. Beaver
On May 24, 2019, the FDA granted regular approval to alpelisib in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Approval was based on the SOLAR-1 study, a randomized, double-blind, placebo-controlled trial of alpelisib plus fulvestrant versus placebo plus fulvestrant. The primary endpoint was investigator-assessed progression-free survival (PFS) per RECIST v1.1 in the cohort of trial participants whose tumors had a PIK3CA mutation. The estimated median PFS by investigator assessment in the alpelisib plus fulvestrant arm was 11 months [95% confidence interval (CI), 7.5–14.5] compared with 5.7 months (95% CI, 3.7–7.4) in the placebo plus fulvestrant arm (HR, 0.65; 95% CI, 0.50–0.85; two-sided P = 0.001). The median overall survival was not yet reached for the alpelisib plus fulvestrant arm (95% CI, 28.1–NE) and was 26.9 months (95% CI, 21.9–NE) for the fulvestrant control arm. No PFS benefit was observed in trial participants whose tumors did not have a PIK3CA mutation (HR, 0.85; 95% CI, 0.58–1.25). The most common adverse reactions, including laboratory abnormalities, on the alpelisib plus fulvestrant arm were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma glutamyl transferase, nausea, increased alanine aminotransferase, fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time, and alopecia.

28 October 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SAShaily Arora
Shaily Arora
PNPreeti Narayan
Preeti Narayan
COChristy L. Osgood
Christy L. Osgood
SWSuparna Wedam
Suparna Wedam
TPTatiana M. Prowell
Tatiana M. Prowell
JBJulia A. Beaver
Julia A. Beaver
Over the last decade, the treatment of patients with breast cancer has been greatly impacted by the approval of multiple drugs and indications. This summary describes 30 FDA approvals of treatments for breast cancer from 2010 to 2020. The trial design endpoints, results, and regulatory considerations are described for each approved indication. Of the 30 indications, 23 (76.6%) received regular and 7 (23.3%) received accelerated approval. Twenty-six approvals were granted in metastatic breast cancer (MBC) and four in early breast cancer. Approval decisions for the 26 MBC indications were initially supported by progression-free survival (PFS) in 21 (80.8%), overall survival (OS) or a combination of OS and PFS in two (7.7%), and objective response rate (ORR) in three (11.5%). The four approvals in early breast cancer utilized pathologic complete response (pCR) in one (25%) and invasive disease-free survival (iDFS) in three (75%) trials. Among the 30 indications, 22 received priority review, seven were granted Breakthrough Therapy Designation, and 10 applications participated in one or more pilot Oncology Center of Excellence regulatory review initiatives, including Real Time Oncology Review, Assessment Aid, and Project Orbis. FDA initiatives to advance breast cancer drug development are also described.

13 November 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JGJennifer J. Gao
Jennifer J. Gao
COChristy L. Osgood
Christy L. Osgood
YGYutao Gong
Yutao Gong
HZHui Zhang
Hui Zhang
EBErik W. Bloomquist
Erik W. Bloomquist
LALaleh Amiri-Kordestani
Laleh Amiri-Kordestani
On June 29, 2020, the FDA approved pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (Phesgo) for the treatment of patients with HER2-positive early-stage and metastatic breast cancer. Patients should be selected for therapy based on an FDA-approved companion diagnostic test. Approval was primarily based on the FeDeriCa trial, a randomized, open-label, multicenter comparability study of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection compared with intravenous pertuzumab and intravenous trastuzumab administered in the neoadjuvant and adjuvant settings with chemotherapy for the treatment of patients with early breast cancer. The pharmacokinetic endpoints were, first, to demonstrate that the exposure of subcutaneous pertuzumab was not inferior to that of intravenous pertuzumab, and then to demonstrate that the exposure of subcutaneous trastuzumab was not inferior to that of intravenous trastuzumab. The primary endpoints were met with the observed lower limit of the two-sided 90% confidence intervals above the prespecified noninferiority margins. The most common adverse reactions were alopecia, nausea, diarrhea, anemia, and asthenia. The totality of the evidence demonstrated comparability of the subcutaneous product to intravenous, allowing for extrapolation and approval of all breast cancer indications for which intravenous trastuzumab and pertuzumab are approved.

14 October 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
PDF file
JGJennifer J Gao
Jennifer J Gao
JCJoyce Cheng
Joyce Cheng
TPTatiana M Prowell
Tatiana M Prowell
EBErik Bloomquist
Erik Bloomquist
STShenghui Tang
Shenghui Tang
LALaleh Amiri-Kordestani
Laleh Amiri-Kordestani